Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
==== Iturins ==== Iturins are pore‐forming lipopeptides with antifungal activity, and this is dependent on the interaction with the cytoplasmic membrane of the target cells. Mycosubtilin is an iturin isoform that can interact with membranes via its sterol alcohol group, to target ergosterol (a compound found in fungi) to give it antifungal properties.
This final incarnation spent seven years performing extensively rearranged material from across the band's entire historical discography, backed by a massive archive of live releases. King Crimson permanently ceased activity at the conclusion of their December 2021 Japanese tour, with Fripp announcing that the band had officially "moved from sound to silence".
Tea is an aromatic beverage prepared by infusion of hot or boiling fresh water with fresh or cured leaves of Camellia sinensis, an evergreen shrub native to East Asia that originated in the borderlands of southwestern China, northeast India and northern Myanmar. Tea has a stimulant effect in humans primarily due to its caffeine content. After plain drinking water, tea is the most widely consumed beverage in the world. There are many varieties of tea according to differences in cultivars, processing and blends; some have a cooling, slightly bitter and astringent flavor, while others have taste profiles that include sweet, nutty, floral or grassy notes. Traditionally, tea is made by steeping loose tea leaves in hot water (usually in a teapot or teacup) for a period of time, or in the case of compressed and fermented tea, via decoction (simmering) in a kettle. Convenient preparations, such as tea bag, infuser and press as well as powdered instant tea such as matcha, konacha and chai latte, are also common. Tea is most commonly consumed as a hot beverage in a plain hot water infusion, although it can also be in mixed drink forms, such as milk tea and butter tea, sometimes sweetened with added sugar or sugar substitutes, or alternatively flavored with salt and spices. In modern times, tea can also be served as a cold beverage in the form of iced tea or in soft drink mixtures such as bubble tea. Early credible record of tea drinking dates to the 3rd century AD, in a Chinese medical text written by Eastern Han dynasty physician Hua Tuo.
Sources: en.wikipedia.org
In the first island chain, Taiwan is considered of critical strategic importance. It is located at the midpoint of the first chain and occupies a strategic position. The 2025 National Security Strategy noted Taiwan's strategic location dividing "Northeast and Southeast Asia into two distinct theatres". Submarine detection and tracking is less difficult on Taiwan's western coast where the waters are shallower than on Taiwan's eastern coast.
== Innovation == The Global Innovation Index 2024, by World Intellectual Property Organization: Thailand ranked 41 of 133 nations. The Global Innovation Index 2019 ranked Thailand 43 of 129 nations. Other ASEAN nations ranked were: Singapore, 8; Malaysia, 35; Vietnam, 42; Philippines, 54; Brunei, 71; Indonesia, 85; Cambodia, 98. The Bloomberg Innovation Index, 2018 ranked Thailand 45 of 50 nations (1=most innovative; 50=less innovative). Singapore was ranked 3 and Malaysia number 26. The Bloomberg Innovation Index, 2017 ranked Thailand 44 of 50 nations (1=most innovative; 50=less innovative), a rise from 47 in the 2016 ranking. Other ASEAN nations ranked were Singapore, 6 of 50 and Malaysia, 23 of 50. The Global Innovation Index 2015 ranked Thailand 55 of 141 (1=best; 141=worst) countries.
== Description == The emu is the second tallest bird in the world, only being exceeded in height by the ostrich; the largest individuals can reach up to 150 to 190 cm (59 to 75 in) in height. Measured from the bill to the tail, emus range in length from 139 to 164 cm (55 to 65 in), with males averaging 148.5 cm (58.5 in) and females averaging 156.8 cm (61.7 in). Emus are the fourth or fifth heaviest living bird after the two species of ostrich and two larger species of cassowary, weighing slightly more on average than an emperor penguin. Adult emus weigh between 18 and 60 kg (40 and 132 lb), with an average of 31.5 and 37 kg (69 and 82 lb) in males and females, respectively. Females are usually slightly larger than males and are substantially wider across the rump.
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section. It appears to work as well as oxytocin. Due to it being less economical than other options, use is not recommended by NHS Scotland. It is given by injection into a vein or muscle. Side effects differ little from that of no treatment or placebo. Use is not recommended in people with epilepsy or eclampsia. Carbetocin is a manufactured long acting form of oxytocin. It works by activating the oxytocin receptor which causes the uterus to contract. Carbetocin was synthesized before 1971 at the Czechoslovak Institute of Organic Chemistry and Biochemistry and was first described by 1974. It was approved for medical use in Canada and the United Kingdom in 1997. It is on the World Health Organization's List of Essential Medicines. It is not available in the United States or Japan.
Sources: en.wikipedia.org
=== Cancer === Scientists have examined EPPK1 expression in multiple types/forms of cancers (bladder, lung, colon, etc.). Various studies show that altered Epiplakin levels in tumor tissues show correlation with tumor progression pathways.
The Italian scholar and physician Girolamo Fracastoro appears to have first used the Latin word fomes, meaning "tinder", in this sense in his essay on contagion, De Contagione et Contagiosis Morbis, published in 1546: "By fomes I mean clothes, wooden objects, and things of that sort, which though not themselves corrupted can, nevertheless, preserve the original germs of the contagion and infect by means of these". English usage of fomes, pronounced , is documented since 1658. The English word fomite, which has been in use since 1859, is a back-formation from the plural fomites (originally borrowed from the Latin plural fōmĭtēs [ˈfoːmɪteːs] of fōmĕs [ˈfoːmɛs]). Over time, the English-language pronunciation of the plural fomites changed from ) to , which led to the creation of a new singular fomite, pronounced . In Latin, fomes (genitive: fomitis, plural fomites, stem fomit-) is a third-declension T-stem noun. Such nouns, like miles/militis or comes/comitis, typically lose their T (thereby becoming a syllable shorter) in the nominative singular, but retain it in all other cases. In languages derived from Latin, the French fomite, Italian fomite, Spanish fómite and Portuguese fómite or fômite, retain the full stem.
One by the Carnegie Endowment for International Peace found that although American Zoomers were not averse to international engagements, they preferred a more modest role for the United States in global affairs, including in dealing with China, Israel, and Ukraine. (See the Second Cold War, Israel's War in Gaza, and the Russo-Ukrainian War.)
== Description == Strobilanthes alternata is a herbaceous plant that reaches approximately 30 cm (12 in) in length. The stems of the plant are prostrate and purplish, especially at the nodes. The leaves, which are covered in fine hairs, are arranged oppositely on the stem with one leaf noticeably larger than its counterpart. The leaf blades are dark green on the top face and are lighter green or purplish on the lower face. Commonly known as the Cemetery plant, Purple waffle plant, or Murikooti, it is referred to in Ayurvedic medicine as Vranaropani, which translates to "wound healer". In Kerala, India, the local name for this herb is Muriyan pacha, a name related to belief in its wound-healing properties. This plant is native to the tropical regions of the globe especially tropical Malaysia and South East Asia. This natural herb grows in plenty across India, China, Indonesia, and Japan
Fatty acids are broken down to CO2 and water by the intra-cellular mitochondria through beta oxidation and the citric acid cycle. In the final step (oxidative phosphorylation), reactions with oxygen release a lot of energy, captured in the form of large quantities of ATP. Many cell types can use either glucose or fatty acids for this purpose, but fatty acids release more energy per gram. Fatty acids (provided either by ingestion or by drawing on triglycerides stored in fatty tissues) are distributed to cells to serve as a fuel for muscular contraction and general metabolism.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.